Clinical Trial Update: A Study for Evaluation of BIV201 to Reduce Ascites and Complications in Patients With Cirrhosis and Refractory Ascites [Phase 2]

View source ↗

Summary

Phase 2 study evaluating BIV201 to reduce ascites and complications in patients with cirrhosis and refractory ascites has been terminated.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Ascites
• Decompensated Cirrhosis

Drugs mentioned

• BIV201

Snippet

Sponsor: BioVie Inc. | Conditions: Ascites, Decompensated Cirrhosis | Phase 2 | Status: TERMINATED